The report complies your views from over 15 countries on the biggest challenges and areas of opportunity in the development, commercialization and adoption of precision medicines, as well as providing in-depth opinion on some of the industries greatest bottlenecks from investment, to regulatory hurdles and Rx-Dx partnering paradigms.
Download your free copy here.
An Interview with… Andreas Stange, Vice President MHS, Global IVD at TÜV SÜD
Andreas Stange sat down to talk all things surrounding the precision medicine and diagnostic community, including the new IVDR, IVD approvals, some of the greatest challenges and more.
Get your copy of the Clinical Biomarkers & World CDx Europe Summit Post Event Report to get the lowdown on 2017’s must-attend event for the Clinical Biomarkers and CDx communities. Gain insight into who attended by industry and seniority; the top session and interview highlights; and find out how you can get involved in 2018.
Flora Berisha, Director, Companion Diagnostics, Daiichi Sankyo
Ralph Graeser, Senior Translational Medicine Expert, Boehringer Ingelheim
Franck Brichory, Associate Director, Personalized Medicine, Debiopharm
Simon Patton, Director, European Molecular Genetics Quality Network
Christian Rolfo, Head of Phase I- Early Clinical Trials Unit, Antwerp University
Luc Van Rompaey, Vice President, Translational Medicine, argenx
Fay McCracken, Advisor, Office for Market Access, NICE
Global Head, Diagnostics, Biomarkers at Roche.